Showing results (181-190 of 2,944) with videos related to
Sort By:
Pageof 295
Expert Review of Cardiovascular Therapy|April 20, 2010
Assessment of endothelial dysfunctionBethan Freestone, Suresh Krishnamoorthy, Gregory Y H LipExpert Opinion on Drug Metabolism & Toxicology|August 19, 2016
Drug-drug interactions of non-vitamin K oral anticoagulantsChristos Voukalis, Gregory Y H Lip, Eduard ShantsilaF1000Research|January 21, 2017
Recent advances in the understanding and management of atrial fibrillation: a focus on stroke preventionFarhan Shahid, Eduard Shantsila, Gregory Y H LipThrombosis Research|February 21, 2021
Effects of antithrombotic drugs on the prothrombotic state in patients with atrial fibrillation: The west Birmingham atrial fibrillation projectChristos Voukalis, Gregory Y H Lip, Eduard ShantsilaAdvances in Cardiology|August 22, 2012
Antiplatelet therapy in stroke preventionStavros Apostolakis, Francisco Marín, Gregory Y H LipAnnals of Internal Medicine|January 6, 2025
In HFpEF, semaglutide reduced a composite of worsening HF or CV deathSteven Ho Man Lam, Gregory Y H Lip, Expert Review of Cardiovascular Therapy|December 21, 2012
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillationYousif Ahmad, Gregory Y H Lip, Stavros ApostolakisPolskie Archiwum Medycyny Wewnetrznej|June 5, 2012
Bleeding risk assessment and management in atrial fibrillation patients. Key messages for clinical practice from the European Heart Rhythm Association position statementYutao Guo, Gregory Y H Lip, Stavros ApostolakisEuropean Heart Journal. Cardiovascular Pharmacotherapy|February 26, 2020
Obesity and atrial fibrillation: making inroads through fatSaad Javed, Dhiraj Gupta, Gregory Y H LipCurrent Opinion in Investigational Drugs (London, England : 2000)|April 6, 2007
Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor XPuneet Kakar, Timothy Watson, Gregory Y H LipPageof 295